POINT Biopharma Global Inc.

POINT Biopharma Global Inc. (Nasdaq: PNT) completed its business combination with GX Acquisition Corp. II, a blank-check company sponsored by GX Capital Management, to become a publicly traded radiopharmaceutical company targeting oncology. GX Acquisition Corp. II completed its IPO in 2020, focusing on the healthcare and life sciences sector. The March 2021 Form 8-K filing, bearing accession number 0001104659-21-035891, marks a key milestone in the de-SPAC transaction that brought POINT Biopharma's pipeline of targeted cancer therapies to public markets. The combined entity operates in the biopharma sector with a concentrated focus on radioligand therapy development. Sign up at SpacDesk for full deal timelines, filing histories, and sponsor data on PNT and hundreds of other SPAC transactions.